Compare NAK & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAK | NTLA |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 986.9M |
| IPO Year | 2002 | 2016 |
| Metric | NAK | NTLA |
|---|---|---|
| Price | $2.02 | $9.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 22 |
| Target Price | $2.50 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 6.5M | 3.6M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $57,528,000.00 |
| Revenue This Year | N/A | $1.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 33.52 |
| 52 Week Low | $0.51 | $5.90 |
| 52 Week High | $2.98 | $28.25 |
| Indicator | NAK | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 43.15 |
| Support Level | $2.01 | $8.74 |
| Resistance Level | $2.44 | $9.62 |
| Average True Range (ATR) | 0.15 | 0.47 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 21.70 | 36.04 |
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.